CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma

doi:10.1016/j.radonc.2015.02.015

Radiotherapy and Oncology

Volume 114, Issue 3, March 2015, Pages 345-350

https://doi.org/10.1016/j.radonc.2015.02.015 Get rights and content

Abstract

Background and purpose

Radiomics provides opportunities to quantify the tumor phenotype non-invasively by applying a large number of quantitative imaging features. This study evaluates computed-tomography (CT) radiomic features for their capability to predict distant metastasis (DM) for lung adenocarcinoma patients.

Material and methods

We included two datasets: 98 patients for discovery and 84 for validation. The phenotype of the primary tumor was quantified on pre-treatment CT-scans using 635 radiomic features. Univariate and multivariate analysis was performed to evaluate radiomics performance using the concordance index (CI).

Results

Thirty-five radiomic features were found to be prognostic (CI > 0.60, FDR < 5%) for DM and twelve for survival. It is noteworthy that tumor volume was only moderately prognostic for DM (CI = 0.55, p-value = 2.77 × 10⁻⁵) in the discovery cohort. A radiomic-signature had strong power for predicting DM in the independent validation dataset (CI = 0.61, p-value = 1.79 × 10⁻¹⁷). Adding this radiomic-signature to a clinical model resulted in a significant improvement of predicting DM in the validation dataset (p-value = 1.56 × 10⁻¹¹).

Conclusions

Although only basic metrics are routinely quantified, this study shows that radiomic features capturing detailed information of the tumor phenotype can be used as a prognostic biomarker for clinically-relevant factors such as DM. Moreover, the radiomic-signature provided additional information to clinical data.

Section snippets

Patient characteristics

This study is an Institutional Review Board-approved analysis of CT for treatment simulation from North-American NSCLC patients receiving chemoRT at our institution from 2001 to 2013. We limited the patient population to pathologically-confirmed lung adenocarcinoma with locally advanced disease (overall stage II–III) [30]. Patients with surgery or chemotherapy before the scheduled radiation therapy planning CT date were excluded from the study. Patients treated before July 2009 were included in

Results

The majority of all patients were female (62.6%) and the median age at start of treatment was 64 years (range: 35–93 years). The median follow-up time was 23.7 months (range: 1.8–119.2 months) and the median survival time was 24.7 months (range: 1.8–119.2 months). The median time to distant metastasis (DM) was 13.4 months (range: 0.3–117.5 months). Patient characteristics, clinical outcomes are shown in Table 1.

Time to DM was similar between Dataset1 and Dataset2 (p-value < 0.36), as for the numbers of

Discussion

Medical imaging gives valuable information for diagnostic, treatment planning or surveillance of cancer patients. Routinely, basic metrics are extracted from these images to utilize as a prognostic factor [27], [28], [29], [30], or to assess treatment response. However, there is much more tumor phenotypic information captured in these images. Radiomics are able to quantify tumor phenotypical differences from medical images by using a large set of imaging features that can be linked to clinical

Disclaimer

None.

Source of support

Authors acknowledge financial support from the National Institute of Health (NIH-USA U01CA190234). Authors acknowledge financial support from the QuIC-ConCePT project, which is partly funded by EFPI A companies and the Innovative Medicine Initiative Joint Undertaking (IMI JU) under Grant Agreement No. 115151. This research is also supported by the Dutch technology Foundation STW (Grant No. 10696 DuCAT), which is the applied science division of NWO, and the Technology Programme of the Ministry

Conflict of interest

None declared.

References (39)

K.S. Albain et al.
Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial
Lancet
(2009)
P. Lambin et al.
Radiomics: extracting more information from medical images using advanced feature analysis
Eur J Cancer
(2012)
V. Kumar et al.
Radiomics: the process and the challenges
Magn Reson Imaging
(2012)
E. Rios Velazquez et al.
A semiautomatic CT-based ensemble segmentation of lung tumors: comparison with oncologists’ delineations and with the surgical specimen
Radiother Oncol
(2012)
M. Vaidya et al.
Combined PET/CT image characteristics for radiotherapy tumor response in lung cancer
Radiother Oncol
(2012)
H.J.W.L. Aerts et al.
Identification of residual metabolic-active areas within NSCLC tumours using a pre-radiotherapy FDG-PET-CT scan: A prospective validation
Lung Cancer
(2012)
W. Van Elmpt et al.
Characterization of tumor heterogeneity using dynamic contrast enhanced CT and FDG-PET in non-small cell lung cancer
Radiother Oncol
(2013)
Y. Balagurunathan et al.
Reproducibility and prognosis of quantitative features extracted from CT images
Transl Oncol
(2014)
D.L. Ball et al.
The complex relationship between lung tumor volume and survival in patients with non-small cell lung cancer treated by definitive radiotherapy: a prospective, observational prognostic factor study of the Trans-Tasman Radiation Oncology Group (TROG 99.05)
Radiother Oncol
(2013)
D. Etiz et al.
Influence of tumor volume on survival in patients irradiated for non—small-cell lung cancer
Int J Radiat Oncol Biol Phys
(2002)

B.M. Alexander et al.

Tumor volume is a prognostic factor in non-small-cell lung cancer treated with chemoradiotherapy

Int J Radiat Oncol Biol Phys

(2011)

R. Siegel et al.

Cancer statistics, 2014: cancer Statistics, 2014

CA Cancer J Clin

(2014)

W.J. Curran et al.

Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410

J Natl Cancer Inst

(2011)

J.D. Bradley et al.

Radiation Therapy Oncology Group: A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy with or without cetuximab for stage III non-small cell lung cancer: Results on radiation dose in RTOG 0617

ASCO Meet Abstr

(2013)

N. Hanna et al.

Phase III Study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non–small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology

J Clin Oncol

(2008)

K. Kelly et al.

Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023

J Clin Oncol Off J Am Soc Clin Oncol

(2008)

P. Lambin et al.

Predicting outcomes in radiation oncology–multifactorial decision support systems

Nat Rev Clin Oncol

(2013)

C. Parmar et al.

Robust radiomics feature quantification using semiautomatic volumetric segmentation

PLoS One

(2014)

R.T.H. Leijenaar et al.

Stability of FDG-PET Radiomics features: An integrated analysis of test-retest and inter-observer variability

Acta Oncol

(2013)

Cited by (570)

Differentiating HCC from ICC and prediction of ICC grade based on MRI deep-radiomics: Using lesions and their extended regions
2024, Physica Medica
This study aimed to evaluate the ability of MRI-based intratumoral and peritumoral radiomics features of liver tumors to differentiate between hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) and to predict ICC differentiation.
This study retrospectively collected 87 HCC patients and 75 ICC patients who were confirmed pathologically. The standard region of interest (ROI) of the lesion drawn by the radiologist manually shrank inward and expanded outward to form multiple ROI extended regions. A three-step feature selection method was used to select important radiomics features and convolution features from extended regions. The predictive performance of several machine learning classifiers on dominant feature sets was compared. The extended region performance was assessed by area under the curve (AUC), specificity, sensitivity, F1-score and accuracy.
The performance of the model is further improved by incorporating convolution features. Compared with the standard ROI, the extended region obtained better prediction performance, among which 6 mm extended region had the best prediction ability (Classification: AUC = 0.96, F1-score = 0.94, Accuracy: 0.94; Grading: AUC = 0.94, F1-score = 0.93, Accuracy = 0.89).
Larger extended region and fusion features can improve tumor predictive performance and have potential value in tumor radiology.
Integration of dosimetric parameters, clinical factors, and radiomics to predict symptomatic radiation pneumonitis in lung cancer patients undergoing combined immunotherapy and radiotherapy
2024, Radiotherapy and Oncology
This study aimed to combine clinical/dosimetric factors and handcrafted/deep learning radiomic features to establish a predictive model for symptomatic (grade ≥ 2) radiation pneumonitis (RP) in lung cancer patients who received immunotherapy followed by radiotherapy.
This study retrospectively collected data of 73 lung cancer patients with prior receipt of ICIs who underwent thoracic radiotherapy (TRT). Of these 73 patients, 41 (56.2 %) developed symptomatic grade ≥ 2 RP. RP was defined per multidisciplinary clinician consensus using CTCAE v5.0. Regions of interest (ROIs) (from radiotherapy planning CT images) utilized herein were gross tumor volume (GTV), planning tumor volume (PTV), and PTV-GTV. Clinical/dosimetric (mean lung dose and V5-V30) parameters were collected, and 107 handcrafted radiomic (HCR) features were extracted from each ROI. Deep learning-based radiomic (DLR) features were also extracted based on pre-trained 3D residual network models. HCR models, Fusion HCR model, Fusion HCR + ResNet models, and Fusion HCR + ResNet + Clinical models were built and compared using the receiver operating characteristic (ROC) curve with measurement of the area under the curve (AUC). Five-fold cross-validation was performed to avoid model overfitting.
HCR models across various ROIs and the Fusion HCR model showed good predictive ability with AUCs from 0.740 to 0.808 and 0.740–0.802 in the training and testing cohorts, respectively. The addition of DLR features improved the effectiveness of HCR models (AUCs from 0.826 to 0.898 and 0.821–0.898 in both respective cohorts). The best performing prediction model (HCR + ResNet + Clinical) combined HCR & DLR features with 7 clinical/dosimetric characteristics and achieved an average AUC of 0.936 and 0.946 in both respective cohorts.
In patients undergoing combined immunotherapy/RT for lung cancer, integrating clinical/dosimetric factors and handcrafted/deep learning radiomic features can offer a high predictive capacity for RP, and merits further prospective validation.
Development and optimisation of a preclinical cone beam computed tomography-based radiomics workflow for radiation oncology research
2023, Physics and Imaging in Radiation Oncology
Radiomics features derived from medical images have the potential to act as imaging biomarkers to improve diagnosis and predict treatment response in oncology. However, the complex relationships between radiomics features and the biological characteristics of tumours are yet to be fully determined. In this study, we developed a preclinical cone beam computed tomography (CBCT) radiomics workflow with the aim to use in vivo models to further develop radiomics signatures.
CBCT scans of a mouse phantom were acquired using onboard imaging from a small animal radiotherapy research platform (SARRP, Xstrahl). The repeatability and reproducibility of radiomics outputs were compared across different imaging protocols, segmentation sizes, pre-processing parameters and materials. Robust features were identified and used to compare scans of two xenograft mouse tumour models (A549 and H460).
Changes to the radiomics workflow significantly impact feature robustness. Preclinical CBCT radiomics analysis is feasible with 119 stable features identified from scans imaged at 60 kV, 25 bin width and 0.26 mm slice thickness. Large variation in segmentation volumes reduced the number of reliable radiomics features for analysis. Standardization in imaging and analysis parameters is essential in preclinical radiomics analysis to improve accuracy of outputs, leading to more consistent and reproducible findings.
We present the first optimised workflow for preclinical CBCT radiomics to identify imaging biomarkers. Preclinical radiomics has the potential to maximise the quantity of data captured in in vivo experiments and could provide key information supporting the wider application of radiomics.
Refining mutanome-based individualised immunotherapy of melanoma using artificial intelligence
2024, European Journal of Medical Research
“All in one” nanoprobe Au-TTF-1 for target FL/CT bioimaging, machine learning technology and imaging-guided photothermal therapy against lung adenocarcinoma
2024, Journal of Nanobiotechnology
Trends and Hotspots in Global Radiomics Research: A Bibliometric Analysis
2024, Technology in Cancer Research and Treatment

View all citing articles on Scopus

¹: Equal contribution.

View full text

CT based radiomic signatureCT-based radiomic signature predicts distant metastasis in lung adenocarcinoma

Abstract

Background and purpose

Material and methods

Results

Conclusions

Section snippets

Patient characteristics

Results

Discussion

Disclaimer

Source of support

Conflict of interest

Lancet

Eur J Cancer

Magn Reson Imaging

Radiother Oncol

Radiother Oncol

Lung Cancer

Radiother Oncol

Transl Oncol

Radiother Oncol

Int J Radiat Oncol Biol Phys

Int J Radiat Oncol Biol Phys

Cancer statistics, 2014: cancer Statistics, 2014

CA Cancer J Clin

Sequential vs. concurrent chemoradiation for stage III non-small cell lung cancer: randomized phase III trial RTOG 9410

J Natl Cancer Inst

Radiation Therapy Oncology Group: A randomized phase III comparison of standard-dose (60 Gy) versus high-dose (74 Gy) conformal chemoradiotherapy with or without cetuximab for stage III non-small cell lung cancer: Results on radiation dose in RTOG 0617

ASCO Meet Abstr

Phase III Study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non–small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology

J Clin Oncol

Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023

J Clin Oncol Off J Am Soc Clin Oncol

Predicting outcomes in radiation oncology–multifactorial decision support systems

Nat Rev Clin Oncol

Robust radiomics feature quantification using semiautomatic volumetric segmentation

PLoS One

Stability of FDG-PET Radiomics features: An integrated analysis of test-retest and inter-observer variability

Acta Oncol

CT based radiomic signature
CT-based radiomic signature predicts distant metastasis in lung adenocarcinoma